US · CGEM
Cullinan Therapeutics, Inc.
- Sector
- Healthcare · Medical - Pharmaceuticals
- Headquarters
- Cambridge, MA 02142
- Website
- cullinantherapeutics.com
Price · as of 2024-12-31
$13.43
Market cap 915.68M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $48.06 | ||||
| 2021 | $13.95 | ||||
| 2022 | $10.89 | $47.75 | |||
| 2023 | $16.79 | ||||
| 2024 | $8.71 |
AI valuation
Our deep-learning model estimates Cullinan Therapeutics, Inc.'s (CGEM) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $13.43
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CGEM | Cullinan Therapeutics, In… | $13.43 | 915.68M | — | — | — | — | -2.79 | 0.79 | — | -0.43 | — | 0.79 | 0.00% | — | — | -32.10% | -214.36% | -30.30% | 0.00 | — | 13.53 | 13.12 | 0.48 | -1572.00% | — | 805.00% | -31.02% | -4.74 | -158.17% | 0.00% | 0.00% | 0.00% | -0.36 | -0.49 | — | 7.79 |
| ADCT | ADC Therapeutics S.A. | $4.10 | 507.9M | +465% | -82% | — | — | -1.13 | -0.88 | 2.52 | -0.50 | — | -0.88 | 91.60% | -184.44% | -222.83% | 89.97% | 41.28% | -46.65% | -0.61 | -2.60 | 3.82 | 3.37 | 1.25 | -4490.00% | 184.00% | 230.00% | -69.75% | -1.54 | 39.40% | 0.00% | 0.00% | 0.00% | -0.39 | -0.41 | 0.72 | -6.56 |
| BCYC | Bicycle Therapeutics plc | $5.73 | 397.02M | +373% | +110% | — | — | -3.52 | 0.75 | 16.88 | 1.67 | — | 0.75 | -390.34% | -594.96% | -479.18% | -29.04% | 217.72% | -21.78% | 0.01 | -121.31 | 13.81 | 13.61 | 5.28 | -4291.00% | 3076.00% | 16112.00% | -27.87% | -2.45 | 177.02% | 0.00% | 0.00% | 65.25% | 1.31 | 1.65 | -7.78 | 1.58 |
| CBLL | CeriBell, Inc. | $18.67 | 692.58M | +73% | +350% | — | — | -12.42 | 3.80 | 7.45 | -10.25 | — | 3.82 | 87.89% | -65.57% | -59.97% | -29.21% | -202.59% | -25.36% | 0.14 | -30.90 | 9.73 | 9.08 | 0.33 | -5693.00% | 3609.00% | 1427.00% | -6.27% | -2.13 | -144.22% | 0.00% | 0.00% | 0.00% | -9.04 | -12.70 | 5.93 | 17.63 |
| EHAB | Enhabit, Inc. | $13.61 | 689.9M | +90% | -75% | — | — | -2.78 | 0.82 | 0.41 | -11.59 | -2.98 | -0.99 | 48.71% | -11.12% | -15.09% | -25.81% | -9.68% | -11.58% | 1.09 | -2.68 | 1.53 | 1.41 | -6.47 | 9317.00% | -110.00% | 557.00% | 11.07% | 0.41 | 4.09% | 0.00% | 0.00% | 9.71% | -8.42 | 20.45 | 0.94 | 1.09 |
| LAB | Standard BioTools Inc. | $1.13 | 434.56M | +2,535% | -50% | -88% | +606% | -5.60 | 0.99 | 4.92 | -2.77 | — | 0.99 | 49.86% | -109.34% | -87.77% | -16.72% | -23.68% | -12.69% | 0.07 | -3588.65 | 4.19 | 1.86 | 0.92 | -6154.00% | -5108.00% | -4555.00% | -19.69% | -0.69 | -34.48% | 0.00% | 0.00% | 0.00% | -2.82 | -3.18 | 3.08 | 2.09 |
| NMRA | Neumora Therapeutics, Inc… | $3.49 | 583.14M | — | — | — | — | -0.97 | 0.83 | — | 0.26 | -36.29 | 0.83 | 0.00% | — | — | -64.48% | -31666.35% | -59.96% | 0.01 | — | 10.51 | 10.29 | 0.53 | 268.00% | — | 1196.00% | -77.03% | -6.12 | -21987.50% | 0.00% | 0.00% | 0.00% | 0.26 | 0.37 | — | -1.09 |
| OMER | Omeros Corporation | $12.05 | 854.35M | — | — | — | — | -2.84 | -2.44 | — | -3.58 | -6.51 | -2.44 | 0.00% | — | — | 151.08% | -341.82% | -47.86% | -1.13 | -6.86 | 1.69 | 1.60 | -1.30 | 4362.00% | — | -30050.00% | -33.43% | -1.87 | -300.85% | 0.00% | 0.00% | 36.52% | -3.32 | -3.78 | — | -5.80 |
| RAPT | RAPT Therapeutics, Inc. | $57.98 | 958.84M | — | — | — | — | -0.35 | 0.24 | — | 1.34 | -7.75 | 0.24 | 0.00% | — | — | -77.09% | 654.65% | -62.79% | 0.02 | — | 4.87 | 4.78 | 1.22 | 458.00% | — | -1503.00% | -181.11% | -1.72 | 401.25% | 0.00% | 0.00% | 270.67% | 1.33 | 2.16 | — | -3.97 |
| SY | So-Young International In… | $3.11 | 410.96M | +89% | -82% | — | — | -1.42 | 0.45 | 0.57 | 2.91 | — | 0.49 | 61.30% | -42.58% | -40.19% | -27.42% | -57.86% | -19.74% | 0.13 | — | 2.74 | 2.24 | 9.06 | -284375.00% | -209.00% | 20752.00% | -10.56% | -0.04 | -8.18% | 5.22% | -7.40% | 15.49% | 0.18 | 1.27 | -0.08 | 0.45 |
| VREX | Varex Imaging Corporation | $13.17 | 552.08M | +77% | -64% | — | — | -6.94 | 1.03 | 0.57 | 209.03 | -15.31 | 1.86 | 34.39% | -3.29% | -8.32% | -13.87% | -3.65% | -6.01% | 0.85 | -0.78 | 3.43 | 1.67 | 73.40 | 4530.00% | 414.00% | -784.00% | 3.88% | 0.22 | 2.47% | 0.00% | 0.00% | 9.24% | -26.32 | 38.91 | 0.87 | 1.63 |
About Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
- CEO
- Nadim Ahmed
- Employees
- 111
- Beta
- -0.10
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $13.43) − 1 = — (DCF, example).